Elsevier

Life Sciences

Volume 324, 1 July 2023, 121742
Life Sciences

Enalapril attenuated CFA provoked arthritic manifestation by modulating proinflammatory and anti-inflammatory cytokine network

https://doi.org/10.1016/j.lfs.2023.121742Get rights and content

Abstract

Enalapril with documented anti-inflammatory potential was evaluated in current investigation to explore its anti-arthritic efficacy. For anti-arthritic evaluation of enalapril, CFA-instigated arthritic model was employed after which various parameters comprising paw volume, body weight, arthritic index, hematological and biochemical parameters, radiographic analysis and level of various cytokines were estimated. Enalapril demonstrated significant (p˂0.001) anti-arthritic activity by suppressing paw volume, arthritic index while preserved CFA instigated weight loss. Likewise, enalapril also normalized the hematological and biochemical alterations, suppressed the level of proinflammatory cytokines with elevation of anti-inflammatory cytokines. Radiographic and histopathological analysis also further validates the anti-arthritic attribute of enalapril where enalapril preserved the normal architecture of arthritis induced joints. Outcomes of the study pointed out a notable anti-arthritic activity of enalapril. However detailed mechanistic studies are still required to point out the exact mechanism of action.

Introduction

Angiotensin converting enzyme (ACE), a halide-activated peptidase, catalyzes the breakdown of substance P and bradykinin as well as responsible for converting angiotensin I to angiotensin II. Angiotensin II, the primary hormone of the rennin-angiotensin system (RAS), exhibits both autocrine and paracrine proinflammatory characteristics [1]. The immune system, as well as inflammatory and degenerative processes, appear to be directly influenced by RAS. T-cells, macrophages, natural killer (NK) cells and dendritic cells are immune system cells that possess angiotensin receptors, thereby, respond to AngII [2]. By promoting the proliferation of progenitor cells, adhesion molecules, and P-selectin, AngII promotes the production of more circulating monocytes. Ang II also regulates the circulation and local concentrations of immune cells [3], [4]. AngII also induces adhesion molecules and P-selectin, which results in the accumulation of immune cells locally. According to these results, AngII is a chemoattractant hormone. It is therefore not surprising that AngII is widely asserted to have a significant role in a variety of autoimmune disorders, such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis [3]. Important pro-inflammatory indicators like interleukin (IL)-6, 8, and TNF-α are upregulated locally by AngII accumulation, and the level of reactive oxygen species is also increased [5]. The key elements of pathological RAS stimulation causing vascular inflammation are NF-ĸB activation and an increase in CRP through ERK1/2 JNK signaling [6]. Furthermore, the widespread distribution of all RAS system components in RA suggests that locally generated Ang II in inflamed knee joints has therapeutic and pathological implications for RA [7]. All these evidences points out a strong implication of RAS and Ang II in the pathobiology of RA. Thereby targetting Ang II might turned out to be a suitable strategy for treating RA manifestations.

Variable outcomes were obtained for earlier clinical studies conducted on ACE inhibitors for their probable role in RA [8], [9], [10]. According to one of preclinical study, the inhibitory action of captopril and quinapril on TNF-α was hypothesized to be the cause of their anti-arthritic efficacy. One study also suggested the anti-arthritic potential of enalapril, but they only estimated the level of IL-1β in arthritic rats. Another study revealed the anti-inflammatory potential of enalapril by modulating IL-1β level while estimating the effect of enalapril on frailty development [11]. Some other studies also documented the anti-inflammatory potential of enalapril [12], [13]. Thus, it can be concluded that enalapril has considerable anti-inflammatory potential that can contribute towrds its ant-arthritic efficacy. However, the exact mechanism by which enalapril might exert its anti-arthritic attribute remained to be identified. Thereby, in the current investigation, we used three different doses of enalapril and targeted a number of pro-inflammatory and anti-inflammatory mediator along with some oxidative stress parameters to point out a more detailed anti-arthritic mechanism of enalapril.

Section snippets

Experimental animals and housing condition

Sprague-Dawley rats weighing 200–250 g were used and kept at a temperature of 25 ± 2 °C under a 12-h light/dark cycle. Before the start of the experiments, there was a seven-day acclimatization phase. Rats were given unlimited access to food and water. The Institutional Animal Ethical Committee of the College of Pharmacy at the University of Sargodha in Pakistan gave its prior consent for the experiments (permission number 22A28 IEC/UOS).

Assessment of enalapril's anti-arthritic potential against CFA instigated arthritis

Arthritis was prompted in all experimental animals by

Paw edema suppression by enalapril treatment

To evaluate the anti-arthritic effect of enalapril CFA induced arthritic model was employed. Outcomes of the study demonstrated a dose dependent anti-arthritic efficacy of enalapril. Enalapril at all the three selected doses (2, 4 and 8 mg/kg) remarkably inhibited paw edema provoked by CFA. At the end of the study period, 28th day, enalapril (8 mg/kg) demonstrated 70.82 % (p˂0.001) inhibition of paw edema compared to arthritic control group. Likewise, enalapril at the dose of 4 mg/kg and

Discussion

Enalapril was employed as an anti-arthritic agent in the current investigation, and CFA induced arthritic model evaluated anti-arthritic efficacy. Enalapril's impact on experimental arthritis has received little attention, although Nikbakht and colleagues' (2007) findings suggest that it can modulate the symptoms of antigen-induced arthritis in rabbits by affecting only IL-1β. Thereby in current investigation, a number of parameters were assessed to point out a detailed mechanism for

Conclusion

Outcomes of the current investigation demonstrated the anti-arthritic activity of enalapril by employing CFA induced arthritic model. Enalapril had suppressive effect on paw inflammation and arthritic score. The body weight and radiological alterations improved with enalapril. Additionally, it normalized the biochemical and hematological markers. Enalapril also demonstrated its antioxidant potential by enhancing the level of CAT, SOD and GSH while suppressing MDA levels. Enalapril's

Funding

This work was funded by Deanship of Scientific Research at Jouf University under Grant number (DSR2022-RG-0145).

Declaration of competing interest

Authors have no conflict of interest to declare.

References (50)

  • D.M. Sluijsmans

    Angiotensin-inhibiting drugs do not impact disease activity in patients with rheumatoid arthritis: a retrospective cross-sectional study

    J. Clin. Med.

    (2021)
  • B. Soós

    Angiotensin converting enzyme activity in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients

    Front. Med.

    (2022)
  • K. Keller

    Chronic treatment with the ACE inhibitor enalapril attenuates the development of frailty and differentially modifies pro-and anti-inflammatory cytokines in aging male and female C57BL/6 mice

    J. Gerontol. A

    (2019)
  • T. Borchert

    Angiotensin-converting enzyme inhibitor treatment early after myocardial infarction attenuates acute cardiac and neuroinflammation without effect on chronic neuroinflammation

    Eur. J. Nucl. Med. Mol. Imaging

    (2020)
  • L.-H. Ding

    Enalapril inhibits tubulointerstitial inflammation and NLRP3 inflammasome expression in BSA-overload nephropathy of rats

    Acta Pharmacol. Sin.

    (2014)
  • S. Qasim

    Appraisal of disease-modifying potential of amlodipine as an anti-arthritic agent: new indication for an old drug

    Inflammopharmacology

    (2020)
  • S. Qasim

    Rosuvastatin attenuates rheumatoid arthritis-associated manifestations via modulation of the pro-and anti-inflammatory cytokine network: a combination of in vitro and in vivo studies

    ACS Omega

    (2021)
  • A.M. Zubair

    Novel acetamide derivatives of 2-aminobenzimidazole prevent inflammatory arthritis in rats via suppression of pro-inflammatory mediators

    Inflammopharmacology

    (2022)
  • H.H. Shaaban

    Diosmin and trolox have anti-arthritic, anti-inflammatory and antioxidant potencies in complete Freund’s adjuvant-induced arthritic male wistar rats: roles of NF-κB, iNOS, Nrf2 and MMPs

    Antioxidants

    (2022)
  • Y. Li et al.

    In vivo and in vitro approach to anti-arthritic and anti-inflammatory effect of crocetin by alteration of nuclear factor-E2-related factor 2/hem oxygenase (HO)-1 and NF-κB expression

    Front. Pharmacol.

    (2018)
  • S. Peng

    Rhoifolin regulates oxidative stress and proinflammatory cytokine levels in Freund’s adjuvant-induced rheumatoid arthritis via inhibition of NF-κB

    Braz. J. Med. Biol. Res.

    (2020)
  • S. Qasim

    Appraisal of the antiarthritic potential of prazosin via inhibition of proinflammatory cytokine TNF-α: a key player in rheumatoid arthritis

    ACS Omega

    (2021)
  • C. Nasuti

    Anti-inflammatory, anti-arthritic and anti-nociceptive activities of Nigella sativa oil in a rat model of arthritis

    Antioxidants

    (2019)
  • M. Ratheesh

    Antioxidant, anti-inflammatory, and anti-arthritic effect of thymoquinone-rich black cumin (Nigella sativa) oil (BlaQmax®) on adjuvant-induced arthritis

    J. Food Res.

    (2021)
  • B. Waksman

    Immune regulation in adjuvant disease and other arthritis models: relevance to pathogenesis of chronic arthritis

    Scand. J. Immunol.

    (2002)
  • View full text